Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia

ELİAÇIK E., Isik A., Aydin C., ÜNER A., AKSU S., SAYINALP N., ...Daha Fazla

HEMATOLOGY, cilt.20, sa.7, ss.392-396, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 7
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1179/1607845414y.0000000221
  • Dergi Adı: HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.392-396
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objectives: The aim of this study was to assess bone marrow (BM) fibrosis and dysplasia in chronic myeloid leukemia (CML) patients receiving the first-generation tyrosine kinase inhibitor (TKI), imatinib, or secondgeneration TKIs, dasatinib, and nilotinib. We further investigated whether CML under TKI is associated with dysplastic BM changes during the clinicopathological course of the disease.